Medivir AB (publ) (STO:MVIR)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.940
+0.010 (0.52%)
At close: Apr 27, 2026
16.45%
Market Cap 1.05B
Revenue (ttm) 8.51M
Net Income (ttm) -94.40M
Shares Out 538.67M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,554,381
Average Volume 4,497,035
Open 1.970
Previous Close 1.930
Day's Range 1.900 - 2.075
52-Week Range 0.340 - 2.885
Beta 0.24
RSI 44.66
Earnings Date Apr 29, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1987
Employees 10
Stock Exchange Nasdaq Stockholm
Ticker Symbol MVIR
Full Company Profile

Financial Performance

In 2025, Medivir AB's revenue was 8.51 million, an increase of 144.14% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.

Financial Statements

News

There is no news available yet.